Abstract
A hallmark of Alzheimer’s disease (AD) is the accumulation of extracellular amyloid-β (Aβ) plaques in the brains of patients. N-terminally truncated pyroglutamate-modified Aβ (pEAβ) has been described as a major compound of Aβ species in senile plaques. pEAβ is more resistant to degradation, shows higher toxicity and has increased aggregation propensity and β-sheet stabilization compared to non-modified Aβ. Here we characterized recombinant pEAβ(3–40) in aqueous trifluoroethanol (TFE) solution regarding its aggregation propensity and structural changes in comparison to its non-pyroglutamate-modified variant Aβ(1–40). Secondary structure analysis by circular dichroism spectroscopy suggests that pEAβ(3–40) shows an increased tendency to form β-sheet-rich structures in 20% TFE containing solutions where Aβ(1–40) forms α-helices. Aggregation kinetics of pEAβ(3–40) in the presence of 20% TFE monitored by thioflavin-T (ThT) assay showed a typical sigmoidal aggregation in contrast to Aβ(1–40), which lacks ThT positive structures under the same conditions. Transmission electron microscopy confirms that pEAβ(3–40) aggregated to large fibrils and high molecular weight aggregates in spite of the presence of the helix stabilizing co-solvent TFE. High resolution NMR spectroscopy of recombinantly produced and uniformly isotope labeled [U-15N]-pEAβ(3–40) in TFE containing solutions indicates that the pyroglutamate formation affects significantly the N-terminal region, which in turn leads to decreased monomer stability and increased aggregation propensity.
Highlights
The pathology of Alzheimer’s disease (AD) is characterized by the presence of intracellular neurofibrillary tangles consisting of accumulated hyperphosphorylated tau protein and extracellular plaques containing amyloid-β (Aβ) as major component [1, 2]
Previous data indicated that pyroglutamate-modified Aβ shows increased tendency to form βsheets compared to the unstructured Aβ in aqueous buffer at neutral pH [22, 48, 49]
We expand structural knowledge on pyroglutamate-modified Aβ (pEAβ)(3–40) by showing that it forms β-sheets even in the presence of considerably amounts of the co-solvent TFE. This is consistent with data indicating that the tendency to build α-helical structures is decreased for pEAβ(3–40) as compared to unstructured Aβ(1–40) as analyzed by proton NMR spectroscopy at higher TFE concentrations, where both peptides stay in monomeric conformation [29]
Summary
The pathology of Alzheimer’s disease (AD) is characterized by the presence of intracellular neurofibrillary tangles consisting of accumulated hyperphosphorylated tau protein and extracellular plaques containing amyloid-β (Aβ) as major component [1, 2]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
